8-K: Pelthos Therapeutics Launches on NYSE American Following Merger, Prepares for ZELSUVMI Commercialization

Ligand Pharmaceuticals announced the completion of its merger with Channel Therapeutics, forming Pelthos Therapeutics Inc., which will commence trading on the NYSE American under PTHS and plans to launch its novel drug ZELSUVMI in July 2025.

Summary

• Ligand Pharmaceuticals Incorporated completed the merger of its wholly-owned subsidiary, LNHC, Inc., with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel Therapeutics Corporation.
• The combined entity will operate as Pelthos Therapeutics Inc. and will begin trading on the NYSE American exchange under the ticker symbol PTHS on July 2, 2025.
• Pelthos plans to launch ZELSUVMI (berdazimer) topical gel, 10.3%, in July 2025 for the treatment of Molluscum contagiosum infections in adults and pediatric patients one year of age and older.
• ZELSUVMI is an FDA-designated novel drug, representing the first and only prescription medication approved for molluscum that can be administered at home.
• Molluscum contagiosum affects an estimated 16.7 million people in the United States.
• Concurrent with the merger, Pelthos raised $50.1 million in equity capital, including a $32 million investment from an Investor Group led by Murchinson and an $18 million investment from Ligand.
• This capital raise included the cancellation of approximately $18.8 million in bridge capital advanced by investors, including Ligand, since early 2025 to support ZELSUVMI's commercial launch.
• Ligand Pharmaceuticals is entitled to a 13% royalty on worldwide net sales of ZELSUVMI.
• Pelthos will also continue to evaluate Channel's existing NaV 1.7 development programs for various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment, announcing the successful completion of a merger, the launch of a new publicly traded company, a significant capital raise, and the imminent commercialization of a novel FDA-approved drug addressing a large unmet medical need. The tone is optimistic about future value creation and product impact.

Positives

• Successful completion of the merger creates a new publicly traded biopharmaceutical company, Pelthos Therapeutics Inc.
• Pelthos is poised for the commercial launch of ZELSUVMI in July 2025, addressing a significant unmet medical need for Molluscum contagiosum infections, which affect an estimated 16.7 million people in the U.S.
• ZELSUVMI is an FDA-designated novel drug and the first and only at-home prescription treatment for molluscum.
• Pelthos secured $50.1 million in equity capital, providing significant funding for the ZELSUVMI launch and future operations.
• Ligand Pharmaceuticals will receive a 13% royalty on worldwide net sales of ZELSUVMI, providing a new revenue stream.
• Ligand's strategic investment and continued guidance, including board representation, indicate ongoing support for Pelthos.

Risks

• There is no guarantee that the trading price of the combined company's Common Stock will be indicative of its value or that it will become an attractive investment in the future.
• Reliance on collaborative partners for milestone payments, royalties, materials revenue, and contract payments, with no guarantee of receiving expected revenue.
• Inability to timely or successfully advance any product(s) in the internal or partnered pipeline or receive regulatory approval.
• Potential lack of a market for product(s) even if successfully developed and approved.
• Changes in general economic conditions, including as a result of war, conflict, epidemic diseases, and the implementation of tariffs.
• Ongoing or future litigation could expose the company to significant liabilities and have a material adverse effect.

Future Outlook

Pelthos Therapeutics Inc. will initially focus on the launch and commercialization of ZELSUVMI for Molluscum contagiosum infections in July 2025, aiming to address a significant unmet medical need. The company also plans to continue evaluating Channel's existing NaV 1.7 development programs for various pain indications. Ligand Pharmaceuticals anticipates long-term value creation for its shareholders through its royalty stream from ZELSUVMI and its continued support for Pelthos.

Management Comments

• "Today marks not just a corporate milestone, but a transformative turning point for the team at Pelthos. With the successful closing of this merger and the launch of Pelthos as an independent, publicly traded biopharmaceutical company, we have unlocked new potential for innovation and long-term value creation for our shareholders. This moment is the result of the vision, hard work, and unwavering commitment of our internal team, who developed the commercial platform to help bring ZELSUVMI, a novel product addressing a significant unmet need, to market this summer. Ligand recognized the potential value of ZELSUVMI before it was approved, during a time when others did not, and we are proud to bring this impactful treatment to market through our special situations initiatives." Todd Davis, CEO of Ligand.
• "Ligand has been an incredible partner over the past few years, and we look forward to their continued guidance and support as members of the Pelthos board. We are excited to begin this new chapter as a publicly traded company and to bring this innovative product to the patients who need it." Scott Plesha, CEO of Pelthos.

Industry Context

This merger and the formation of Pelthos Therapeutics Inc. represent a strategic move in the biopharmaceutical industry, creating a new specialized entity focused on commercializing a novel FDA-approved drug for a common dermatological condition. The capital raise and the royalty agreement highlight a common financing and partnership model in biotech, where established companies like Ligand leverage their expertise and capital to spin out or support new ventures, retaining a financial interest in successful product launches. The focus on ZELSUVMI addresses a significant unmet need in the molluscum contagiosum market, potentially establishing Pelthos as a key player in pediatric dermatology. The continued evaluation of NaV 1.7 programs also indicates a broader interest in pain management, a highly competitive but lucrative therapeutic area.

Legal Proceedings

• Ongoing or future litigation could expose the company to significant liabilities and have a material adverse effect.

Related Party Transactions

• Ligand Pharmaceuticals invested $18 million in Pelthos, and also advanced bridge capital (part of the $18.8 million cancelled) to Pelthos since early 2025, indicating a related party transaction as Ligand is a significant investor and former parent of the spun-off entity.

Stakeholder Impact

• Shareholders (Ligand): Expected to benefit from long-term value creation through the 13% royalty on ZELSUVMI sales and their investment in Pelthos.
• Shareholders (Pelthos/Channel): Will now hold shares in a newly public company, Pelthos, with a new ticker symbol (PTHS) and a significant capital infusion for operations and product launch.
• Patients: Will gain access to ZELSUVMI, the first and only at-home prescription treatment for Molluscum contagiosum, addressing a significant unmet medical need.
• Employees (Pelthos): Will be part of a newly formed, independent, publicly traded biopharmaceutical company with a clear focus on product commercialization and pipeline development.

Next Steps

• Pelthos Therapeutics Inc. will commence trading on the NYSE American exchange under the ticker symbol PTHS on July 2, 2025.
• Pelthos will initially focus on the launch and commercialization of ZELSUVMI (berdazimer) topical gel, 10.3%, for Molluscum contagiosum infections in July 2025.
• Pelthos is continuing to evaluate the path forward for Channel's existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.

Key Dates

Recommendation

Keywords

Pelthos Therapeutics, Ligand Pharmaceuticals, Channel Therapeutics, Merger, Biopharmaceutical, ZELSUVMI, Molluscum contagiosum, Drug launch, FDA approval, Royalty, Equity capital, NYSE American, PTHS, LGND, NaV 1.7, Pain treatment, Dermatology